Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasin, Ayse Irem, Aydin, Sabin Göktas, Sümbül, Bilge, Koral, Lokman, Şimşek, Melih, Geredeli, Çağlayan, Öztürk, Akın, Perkin, Perihan, Demirtaş, Derya, Erdemoglu, Engin, Hacıbekiroglu, İlhan, Çakır, Emre, Tanrıkulu, Eda, Çoban, Ezgi, Ozcelik, Melike, Çelik, Sinemis, Teker, Fatih, Aksoy, Asude, Fırat, Sedat T, Tekin, Ömer, Kalkan, Ziya, Türken, Orhan, Oven, Bala B, Dane, Faysal, Bilici, Ahmet, Isıkdogan, Abdurrahman, Seker, Mesut, Türk, Hacı M, Gümüş, Mahmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793921/
https://www.ncbi.nlm.nih.gov/pubmed/35081732
http://dx.doi.org/10.2217/fon-2021-1248
Descripción
Sumario:Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: NCT04771559 (ClinicalTrials.gov)

Ejemplares similares